Proarrhythmia of azimilide and other class III antiarrhythmic agents in the adrenergically stimulated rabbit

Proceedings of the Society for Experimental Biology and Medicine

Volumn 223, Issue 2, 2000, Pages 183-189

  Brooks, Robert R ^a   Drexler, Anne P ^a   Maynard, Anne E ^a   Al Khalidi, Hussein ^a   Kostreva, David R ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; AZIMILIDE; CLOFILIUM; DOFETILIDE; SEMATILIDE; SOTALOL;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; FEMALE; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; MALE; NONHUMAN; QT INTERVAL; RABBIT;

EID: 0034038563     PISSN: 00379727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1373.2000.22325.x     Document Type: Article

References (20)

1. McIntosh MA, Tanira M, Pacini D, Kane KA. Comparison of the cardiac electrophysiologic effects of NE-10064 with sotalol and E-4031 and their modification by simulated ischaemia. J Cardiovasc Pharmacol 23:653-657, 1994.
2. Fermini B, Jurkiewicz NK, Jow B, Guinosso PJ Jr., Baskin EP, Lynch JJ Jr., Salata JJ. Use-dependent effects of the class III antiarrhythmic agent NE-10064 (azimilide) on cardiac repolarization: Block of delayed rectifier potassium and L-type calcium currents. J Cardiovasc Pharmacol 26:259-271, 1995.
3. Salata JJ, Brooks RR. Pharmacology of azimilide dihydrochloride (NE-10064). Cardiovasc Drug Rev 15:137-156, 1997.
4. Brooks RR, Carpenter JF, Miller KE, Maynard AE. Efficacy of the class III antiarrhythmic agent azimilide in rodent models of ventricular arrhythmia. Proc Soc Exp Biol Med 212:84-93, 1996.
5. Drexler AP, Micklas JM, Brooks RR. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction. J Cardiovasc Pharmacol 28:848-855, 1996.
6. Black SC, Butterfield JL, Lucchesi BR. Protection against programmed electrical stimulation-induced ventricular tachyarrhythmia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug. J Cardiovasc Pharmacol 22:810-818, 1993.
7. Pritchett E, Page R, Connolly S, Marcello S, Schnell D, Wilkinson W, ASAP Investigators. Azimilide treatment of atrial fibrillation. (abstract) Circulation 17:1-633, 1998.
8. Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE, Pritchett ELC, ASAP Investigators. Dose response for azimilide treatment of paroxysmal supraventricular tachycardia. (abstract) Pacing Clin Electrophysiol 44:770, 1999.
9. Stanton MS, Prystowsky EN, Fineberg NS, Miles WM, Zipes DP, Heger JJ. Arrhythmogenic effects of antiarrhythmic drugs: A study of 506 patients treated for ventricular tachycardia or fibrillation. J Am Coll Cardiol 14:209-215, 1989.
10. Roden DM. Early after-depolarizations and torsade de pointes: Implications for the control of cardiac arrhythmias by prolonging repolarization. Eur Heart J 14:56-61, 1993.
11. Kr: Implications for torsade de pointes and reverse use-dependence. Circulation 93:407-411, 1996.
12. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 16:276-285, 1990.
13. Buchanan LV, Kabell G, Brunden MN, Gibson JK. Comparative assessment of ibutilide, d-sotalol, clofilium, E-4031, and UK-68,798 in a rabbit model of proarrhythmia. J Cardiovasc Pharmacol 22:540-549, 1993.
14. Al-Khalidi H, Schnell DJ. Application of a continuous-time Markov chain to a preclinical study. Drug Inf J 31:607-613, 1997.
15. Al-Khalidi H, Drexler AP, Kostreva DR, Brum JM. Proarrhythmic effects of the class III antiarrhythmic drugs using continuous-time Markov chain model. (abstract) Pacing Clin Electrophysiol 20:1233, 1997.
16. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart J 7:353-370, 1920.
17. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early after-depolarisations. Cardiovasc Res 27:2186-2193, 1993.
18. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffolo RR. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. J Pharmacol Exp Ther 276:637-646, 1996.
19. Ks. Am J Physiol 271:H2477-H2489, 1996.
20. Soyka LF, Wirtz C, Spangenberg RB. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 65:74A-81A, 1990.